Prescription Pattern of Acid Suppressive Medications in Bangladesh

Abstract

Gastrointestinal disorders, specifically acid-related disorders including gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and dyspepsia are very common in Bangladesh. About 16% of patients are suffering from gastrointestinal acid related disorders .According to 4P data (Product, Place, price & Promotion) from 4P Marketing Consultancy, Bangladesh, June, 2012 it is reported that 16.71% of patients are suffering from gastrointestinal acid related disorders. Their findings come from prescription-based study (7 lac prescriptions) .This data may focus on the prevalence of acid-related disorders in Bangladesh like Peptic ulcer diseases, Dyspepsia, etc. The results demonstrated 16.71% of this patient population had acid-related disorders, where male patients is 15.42%, Female patients is 17.73% and different aged group patients is in different percentages. Current treatment guidelines for acid-related diseases (ARDs) recommend first-line treatment with a proton pump inhibitor (PPI) to reduce gastric acid production. PPIs are indicated in the management of gastroesophageal reflux disease (reflux esophagitis, nonerosive reflux disease), peptic ulcer (gastric and duodenal ulcer, non-steroidal anti-inflammatory drug (NSAID)-associated ulcer, bleeding ulcer), functional dyspepsia, and in association with Helicobacter pylori eradication therapy when needed. Currently, PPIs (omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole) are widely used for the treatment of ARDs. All 5 PPIs are effective. However, there are differences in PPI pharmacokinetic and pharmacodynamic profiles that might influence their clinical utility. In Bangladesh total anti ulcerants market value is very large with high growth. According to IMS data, 4Q 2011, Total antiulcerant market is about 12090 million Tk with 31.64 % growth. Antiulcerant market share is 14%. Absolutely this share is very high. Whereas only Proton Pump inhibitors’ market is 9500 million taka with 37.71 % growth.